PL3336097T3 - Wytwarzanie niekrystalicznej postaci kwasu obetycholowego - Google Patents

Wytwarzanie niekrystalicznej postaci kwasu obetycholowego

Info

Publication number
PL3336097T3
PL3336097T3 PL17202916T PL17202916T PL3336097T3 PL 3336097 T3 PL3336097 T3 PL 3336097T3 PL 17202916 T PL17202916 T PL 17202916T PL 17202916 T PL17202916 T PL 17202916T PL 3336097 T3 PL3336097 T3 PL 3336097T3
Authority
PL
Poland
Prior art keywords
preparation
crystalline form
obeticholic acid
obeticholic
acid
Prior art date
Application number
PL17202916T
Other languages
English (en)
Inventor
André STEINER
Heidi Waenerlund Poulsen
Emilie JOLIBOIS
Melissa REWOLINSKI
Ralf Gross
Emma Sharp
Fiona DUBAS-FISHER
Alex Eberlin
Original Assignee
Intercept Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48741553&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3336097(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intercept Pharmaceuticals, Inc. filed Critical Intercept Pharmaceuticals, Inc.
Publication of PL3336097T3 publication Critical patent/PL3336097T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL17202916T 2012-06-19 2013-06-17 Wytwarzanie niekrystalicznej postaci kwasu obetycholowego PL3336097T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261661531P 2012-06-19 2012-06-19
EP17202916.7A EP3336097B1 (en) 2012-06-19 2013-06-17 Preparation of the non-crystalline form of obeticholic acid
PCT/US2013/046150 WO2013192097A1 (en) 2012-06-19 2013-06-17 Preparation, uses and solid forms of obeticholic acid
EP13733181.5A EP2861613A1 (en) 2012-06-19 2013-06-17 Preparation, uses and solid forms of obeticholic acid

Publications (1)

Publication Number Publication Date
PL3336097T3 true PL3336097T3 (pl) 2021-05-31

Family

ID=48741553

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17202916T PL3336097T3 (pl) 2012-06-19 2013-06-17 Wytwarzanie niekrystalicznej postaci kwasu obetycholowego

Country Status (25)

Country Link
US (9) US9238673B2 (pl)
EP (4) EP3992201A1 (pl)
JP (6) JP2015521621A (pl)
KR (4) KR20190121871A (pl)
CN (2) CN104781272A (pl)
AU (5) AU2013277429B2 (pl)
BR (2) BR122016011808B1 (pl)
CA (3) CA3028207A1 (pl)
CL (2) CL2014003475A1 (pl)
CO (1) CO7240414A2 (pl)
DK (1) DK3336097T3 (pl)
EA (2) EA032347B1 (pl)
ES (1) ES2822375T3 (pl)
HK (1) HK1211296A1 (pl)
IL (3) IL236231A0 (pl)
IN (1) IN2014MN02561A (pl)
MX (2) MX365059B (pl)
NZ (3) NZ734451A (pl)
PH (1) PH12014502835A1 (pl)
PL (1) PL3336097T3 (pl)
PT (1) PT3336097T (pl)
SG (3) SG10201607230SA (pl)
SI (1) SI3336097T1 (pl)
TW (1) TWI673284B (pl)
WO (1) WO2013192097A1 (pl)

Families Citing this family (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1392714B1 (en) 2001-03-12 2005-08-31 Intercept Pharmaceuticals, Inc. Steroids as agonists for fxr
US9719068B2 (en) 2010-05-06 2017-08-01 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
SG10201607230SA (en) 2012-06-19 2016-10-28 Intercept Pharmaceuticals Inc Preparation, Uses And Solid Forms Of Obeticholic Acid
BR112015012312A2 (pt) * 2012-11-28 2017-07-11 Intercept Pharmaceuticals Inc método de tratamento, redução do risco, prevenção ou alívio de uma afecção ou doença pulmonar em um sujeito; método de redução ou supressão de inflamação no pulmão em um sujeito; e método de promoção de reparo pulmonar em um sujeito
US9814733B2 (en) * 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
HRP20190232T1 (hr) 2013-04-17 2019-03-22 Sage Therapeutics, Inc. 19-nor c3,3-disupstituirani c21-n-pirazolil steroidi i postupci za njihovu upotrebu
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
HRP20200995T1 (hr) 2013-04-17 2020-11-27 Sage Therapeutics, Inc. 19-nor neuroaktivni steroidi za metode liječenja
SMT202100229T1 (it) 2013-07-19 2021-05-07 Sage Therapeutics Inc Steroidi neuroattivi, composizioni e loro usi
SMT202100048T1 (it) 2013-08-23 2021-03-15 Sage Therapeutics Inc Steroidi neuroattivi, composizioni e loro usi
SG10201801654RA (en) 2014-05-28 2018-04-27 Childrens Hospital Med Ct Methods and systems for converting precursor cells into gastric tissues through directed differentiation
WO2015181275A1 (en) 2014-05-29 2015-12-03 Bar Pharmaceuticals S.R.L. Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2016045480A1 (zh) * 2014-09-28 2016-03-31 上海源力生物技术有限公司 一种奥贝胆酸的制备方法
AU2015331749A1 (en) 2014-10-16 2017-05-04 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
JP6742308B2 (ja) 2014-10-16 2020-08-19 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ障害を処置するための組成物および方法
AU2015331848B2 (en) 2014-10-17 2022-03-03 Children's Hospital Medical Center, D/B/A Cincinnati Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
BR112017009657A2 (pt) 2014-11-06 2018-01-23 Enanta Pharmaceuticals, Inc análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos
WO2016079520A1 (en) 2014-11-19 2016-05-26 Dextra Laboratories Limited 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators
MX375864B (es) 2014-11-19 2025-03-07 Nzp Uk Ltd Esteroides de 5.beta-6-alquil-7-hidroxi-3-ona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr)
KR102526631B1 (ko) 2014-11-19 2023-04-27 엔제트피 유케이 리미티드 스테로이드 fxr 조절인자를 제조하기 위한 중간체로서의 6-알킬-7-하이드록시-4-엔-3-온 스테로이드
CN107108688B (zh) * 2014-11-19 2019-10-29 Nzp英国有限公司 作为制备类固醇FXR调节剂的中间体的6α-烷基-3,7-二酮类固醇
WO2016086115A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
CA2968404A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
ES2793237T3 (es) 2014-11-27 2020-11-13 Sage Therapeutics Inc Composiciones y métodos para el tratamiento de trastornos del SNC
CN105777835B (zh) * 2014-12-25 2020-02-14 重庆药友制药有限责任公司 一种制备鹅去氧胆酸类似物的方法
CN105801653B (zh) * 2014-12-30 2018-04-17 苏州晶云药物科技有限公司 奥贝胆酸的晶型a及其制备方法
CN105859814A (zh) * 2015-01-23 2016-08-17 江苏奥赛康药业股份有限公司 一种奥贝胆酸化合物及其药物组合物
SI3250210T1 (sl) 2015-01-26 2021-07-30 Sage Therapeutics, Inc. Sestavki in metode za zdravljenje CNS motenj
AR103624A1 (es) 2015-02-06 2017-05-24 Intercept Pharmaceuticals Inc Composiciones farmacéuticas para terapia de combinación
RU2017130466A (ru) 2015-02-11 2019-03-12 Энанта Фармасьютикалс, Инк. Аналоги желчной кислоты в качестве агонистов fxr/tgr5 и способы их применения
CN105985395A (zh) * 2015-02-13 2016-10-05 江苏奥赛康药业股份有限公司 一种奥贝胆酸化合物及含有该化合物的药物组合物
CN105985396A (zh) * 2015-02-16 2016-10-05 苏州泽璟生物制药有限公司 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
US10329320B2 (en) 2015-02-20 2019-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP3268009A4 (en) * 2015-03-09 2018-12-12 Intercept Pharmaceuticals, Inc. Methods for modulating bone density
SI3277286T1 (sl) 2015-03-31 2021-09-30 Enanta Pharmaceuticals, Inc. Derivati žolčne kisline kot antagonisti FXR/TGR5 in metode za njihovo uporabo
CA2981507A1 (en) 2015-04-07 2016-10-13 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions for combination therapy
CN105777836A (zh) * 2015-04-09 2016-07-20 厦门蔚扬药业有限公司 奥贝胆酸的多晶型物及其制备方法
WO2016168553A1 (en) * 2015-04-17 2016-10-20 Concert Pharmaceuticals, Inc. Deuterated obeticholic acid
PE20180690A1 (es) * 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
CN106290594B (zh) * 2015-05-27 2020-07-17 中美华世通生物医药科技（武汉）有限公司 测定奥贝胆酸片溶出含量的方法
CN105294801A (zh) * 2015-07-02 2016-02-03 扬子江药业集团南京海陵药业有限公司 6-乙基鹅去氧胆酸异构体的合成及其分离测定方法
CZ2015504A3 (cs) 2015-07-16 2017-01-25 Zentiva, K.S. Krystalické formy obeticholové kyseliny
EP3124080A1 (en) * 2015-07-28 2017-02-01 Merz Pharma GmbH & Co. KGaA Semisynthetic bile acids for injection lipolysis
CN105085597B (zh) * 2015-08-28 2017-03-29 成都百裕制药股份有限公司 一种无定型奥贝胆酸的制备方法
CN106478756A (zh) * 2015-09-02 2017-03-08 中美华世通生物医药科技（武汉）有限公司 Oca-e单晶及其制备方法和用途
WO2017053428A1 (en) * 2015-09-21 2017-03-30 Intercept Pharmaceuticals, Inc. Methods of promoting hepatic regeneration
HK1254057A1 (zh) 2015-09-24 2019-07-12 英特塞普特医药品公司 用於制备胆汁酸衍生物的方法和中间体
CN108348530B (zh) 2015-10-07 2023-09-29 英特塞普特医药品公司 法尼醇x受体调节剂
CN106589038A (zh) * 2015-10-15 2017-04-26 重庆医药工业研究院有限责任公司 一种制备3α,7α-二羟基-6α-乙基-5β-胆烷酸的方法
CN106589039B (zh) * 2015-10-15 2019-12-17 苏州朗科生物技术股份有限公司 一种奥贝胆酸的制备方法及相关化合物
CN106632564B (zh) * 2015-10-30 2021-04-13 苏州泽璟生物制药股份有限公司 奥贝胆酸盐及其无定形物和药物组合物
CN106668027A (zh) * 2015-11-05 2017-05-17 中美华世通生物医药科技（武汉）有限公司 奥贝胆酸药物组合物及其制备方法
EP3370728A4 (en) * 2015-11-06 2019-07-10 Intercept Pharmaceuticals, Inc. PROCESS FOR THE PREPARATION OF OBETICHOLIC ACID AND DERIVATIVES THEREOF
CN106749466B (zh) * 2015-11-23 2019-05-21 南京济群医药科技股份有限公司 一种高纯度奥贝胆酸的制备方法
CN105315320B (zh) * 2015-11-30 2017-03-08 山东省药学科学院 一种制备奥贝胆酸的方法
CN106810586A (zh) * 2015-12-01 2017-06-09 中美华世通生物医药科技（武汉）有限公司 奥贝胆酸晶型ⅱ及其制备方法和用途
CN106810587A (zh) * 2015-12-01 2017-06-09 中美华世通生物医药科技（武汉）有限公司 制备无定型奥贝胆酸的方法
CN106822005A (zh) * 2015-12-03 2017-06-13 江苏先声药业有限公司 奥贝胆酸组合物及其制备方法
CN106854229A (zh) * 2015-12-08 2017-06-16 陈剑 一类脂肪酸盐,其制备及其在医药上的应用
CN105481925B (zh) * 2015-12-17 2018-06-22 南京济群医药科技股份有限公司 一种奥贝胆酸及其中间体的制备方法
MX2018007776A (es) * 2015-12-22 2018-08-09 Intercept Pharmaceuticals Inc Formas polimorficas cristalinas del acido obeticolico.
CN105399793A (zh) * 2015-12-24 2016-03-16 北京康立生医药技术开发有限公司 一种胆烷酸的制备方法
CN106916195A (zh) * 2015-12-25 2017-07-04 中美华世通生物医药科技（武汉）有限公司 奥贝胆酸中间体的纯化方法
WO2017115324A1 (en) * 2016-01-01 2017-07-06 Lupin Limited Solid forms of obeticholic acid and processes thereof
CN105646633B (zh) * 2016-01-22 2020-05-26 南京长澳医药科技有限公司 一种制备奥贝胆酸1型的方法
CN105566429B (zh) * 2016-01-22 2020-12-01 南京长澳医药科技有限公司 一种奥贝胆酸1型的制备方法
CN105646634A (zh) * 2016-01-29 2016-06-08 中国药科大学 奥贝胆酸杂质的制备方法
JP6842474B2 (ja) * 2016-02-02 2021-03-17 深▲セン▼市塔吉瑞生物医▲薬▼有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ，Ｉｎｃ． ステロイド系化合物、当該化合物を含む組成物及びその使用
CN108697700B (zh) * 2016-02-04 2021-08-17 辛多美制药有限公司 氘代多潘立酮组合物和用于治疗病症的方法
US11364226B2 (en) 2017-06-30 2022-06-21 Cinrx Pharma, Llc Deuterated domperidone compositions, methods, and preparation
CN108779141A (zh) * 2016-02-10 2018-11-09 雷迪博士实验室有限公司 奥贝胆酸的胺盐
US10364267B2 (en) 2016-02-23 2019-07-30 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
US10323061B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof
WO2017147137A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
CN107126419B (zh) * 2016-02-26 2020-06-19 石药集团中诺药业（石家庄）有限公司 一种奥贝胆酸片剂及其制备方法
CN109467585A (zh) * 2016-03-11 2019-03-15 深圳市塔吉瑞生物医药有限公司 用于预防或治疗fxr-介导疾病的胆烷酸化合物
CN105541953B (zh) * 2016-03-15 2017-11-21 成都市新功生物科技有限公司 一种高纯度奥贝胆酸的重结晶纯化方法
CN107188917A (zh) * 2016-03-15 2017-09-22 正大天晴药业集团股份有限公司 奥贝胆酸盐及其药物组合物
WO2017170434A1 (ja) * 2016-03-28 2017-10-05 大日本住友製薬株式会社 Ｆｘｒアゴニストとａｒｂの組み合わせ医薬
CN107531744B (zh) * 2016-03-31 2020-03-13 江苏恒瑞医药股份有限公司 一种奥贝胆酸的新结晶形式及其制备方法
US11331273B2 (en) 2016-03-31 2022-05-17 Intercept Pharmaceuticals, Inc. Film-coated tablet having high chemical stability of active ingredient
CN109152787A (zh) * 2016-03-31 2019-01-04 英特塞普特医药品公司 具有优越的溶出性的口服制剂
EP3228306A1 (en) 2016-04-04 2017-10-11 ratiopharm GmbH Complex compound comprising obeticholic acid and cyclodextrin and pharmaceutical formulation comprising the complex compound
US10752654B2 (en) 2016-04-04 2020-08-25 Dipharma Francis S.R.L. Method for preparing a farnesoid X receptor agonist
TW201738254A (zh) * 2016-04-19 2017-11-01 英特賽普醫藥品公司 奧貝膽酸及其衍生物之製備方法
CN109415685B (zh) 2016-05-05 2023-07-04 儿童医院医疗中心 用于体外制造胃底组织的方法和与其相关的组合物
CN105859817A (zh) * 2016-05-09 2016-08-17 成都宇西医药技术有限公司 一种制备3α-羟基-6-乙烯基-7-酮基-5β-胆烷酸的方法
CN107400154A (zh) * 2016-05-18 2017-11-28 北京凯因科技股份有限公司 一种制备3α,7α-二-羟基-6α-乙基-5β-胆烷酸的方法
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
CN106046094A (zh) * 2016-05-30 2016-10-26 福建广生堂药业股份有限公司 一种奥贝胆酸二聚体杂质及其制备方法
CN105859818A (zh) * 2016-05-31 2016-08-17 四川瑞希康生物医药有限公司 一种奥贝胆酸α晶型及其制备方法、药物组合物和用途
WO2017208165A1 (en) 2016-06-01 2017-12-07 Dr. Reddy’S Laboratories Limited Process for preparation of obeticholic acid
CN105997909A (zh) * 2016-06-02 2016-10-12 中国药科大学 一种奥贝胆酸口崩片及其制备方法
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
ES2921432T3 (es) 2016-06-13 2022-08-25 Gilead Sciences Inc Derivados de azetidina como moduladores de FXR (NR1H4)
CN106083971B (zh) * 2016-06-17 2017-11-14 苏州敬业医药化工有限公司 一种(E)‑3α‑羟基‑6‑亚乙基‑7‑酮‑5β‑胆烷‑24‑酸的制备方法
CZ2016385A3 (cs) 2016-06-28 2018-01-10 Zentiva, K.S. Způsoby přípravy intermediátů pro syntézu Obeticholové kyseliny
CN107540720B (zh) * 2016-06-29 2021-03-02 常州市第四制药厂有限公司 3α,7α-二羟基-6α-乙基-5β-胆烷酸晶型H及其制备方法和应用
CN109689673B (zh) 2016-07-11 2023-03-14 萨奇治疗股份有限公司 C17、c20和c21取代的神经活性类固醇及其使用方法
AU2017296295B2 (en) 2016-07-11 2022-02-24 Sage Therapeutics, Inc. C7, C12, and C16 substituted neuroactive steroids and their methods of use
CN107648190B (zh) * 2016-07-26 2021-04-27 海南先声药业有限公司 奥贝胆酸组合物及其制备方法
CN106279331B (zh) * 2016-07-27 2019-06-14 宋火良 胆酸类肝病治疗药物
CN107674106B (zh) * 2016-08-01 2021-06-22 华北制药集团新药研究开发有限责任公司 一种奥贝胆酸二聚体的制备方法
CN106279335A (zh) * 2016-08-12 2017-01-04 齐鲁制药有限公司 一种制备奥贝胆酸及其中间体的方法
EP3287467A1 (en) 2016-08-22 2018-02-28 ratiopharm GmbH Preparation of obeticholic acid comprising continuous flow process steps
CN115490744A (zh) * 2016-08-29 2022-12-20 山东新时代药业有限公司 一种3α-羟基-6α-乙基-7-酮-5β-胆-24-酸的制备方法
CN107778339A (zh) * 2016-08-29 2018-03-09 鲁南制药集团股份有限公司 一种无定型奥贝胆酸的制备方法
EP3293196A1 (en) 2016-09-09 2018-03-14 Hexal AG Process for purifying obeticholic acid
CN106478757B (zh) * 2016-09-27 2019-01-18 华南理工大学 一种3α,7α-二羟基-6α-乙基胆烷酸的制备方法
KR20190057108A (ko) * 2016-09-30 2019-05-27 인터셉트 파마슈티컬즈, 인크. 담즙산 유도체의 결정형
CN107976506B (zh) * 2016-10-25 2020-05-12 成都弘达药业有限公司 一种奥贝胆酸有关物质的检测方法
EP3534976A4 (en) 2016-11-04 2020-09-16 Children's Hospital Medical Center PATHOLOGICAL MODELS OF HEPATIC ORGANOIDS AND ASSOCIATED METHODS OF MANUFACTURE AND USE
US10584145B2 (en) 2016-11-29 2020-03-10 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonylurea bile acid derivatives
CA3045145A1 (en) 2016-12-05 2018-06-14 Children's Hospital Medical Center Colonic organoids and methods of making and using same
WO2018104916A1 (en) * 2016-12-09 2018-06-14 Cadila Healthcare Limited Treatment for primary biliary cholangitis
CN108614038B (zh) * 2016-12-13 2022-05-17 亚宝药业集团股份有限公司 一种测定奥贝胆酸原料药有关物质的方法
CN106749472B (zh) * 2016-12-30 2019-02-22 江苏开元医药化工有限公司 一种3α-羟基-6α-乙基-7-酮-5β-胆烷-24-酸的制备方法
CN106645497A (zh) * 2017-01-03 2017-05-10 山东省药学科学院 一种奥贝胆酸及其制剂中有关物质的检测方法
MX2019008510A (es) 2017-01-18 2019-11-11 Tremco Inc Compuesto de union estructural.
WO2018152171A1 (en) 2017-02-14 2018-08-23 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr agonists and methods of use thereof
CN106892954B (zh) * 2017-02-23 2019-04-30 广州隽沐生物科技有限公司 奥贝胆酸的制备工艺
AU2018230350A1 (en) * 2017-03-08 2019-09-26 Intercept Pharmaceuticals, Inc Crystalline forms of obeticholic acid
EP4424364B1 (en) 2017-03-28 2026-01-21 Gilead Sciences, Inc. Combinations for use in the treatment of cirrhosis and liver fibrosis
CN108659086A (zh) * 2017-03-29 2018-10-16 杭州源昶医药科技有限公司 一种奥贝胆酸的合成方法
ES2971092T3 (es) 2017-04-07 2024-06-03 Enanta Pharm Inc Procedimiento para la preparación de derivados de ácidos biliares de carbamato de sulfonilo
WO2018191673A1 (en) 2017-04-14 2018-10-18 Children's Hospital Medical Center Multi donor stem cell compositions and methods of making same
CN106986910A (zh) * 2017-04-19 2017-07-28 成都百特万合医药科技有限公司 奥贝胆酸中间体的制备方法
JP6987967B2 (ja) * 2017-04-20 2022-01-05 デーウン・バイオ・インコーポレイテッド 連続フロー反応を利用した胆汁酸誘導体の製造方法
WO2018211413A1 (en) * 2017-05-15 2018-11-22 Dr. Reddy’S Laboratories Limited Solid forms of obeticholic acid and process for preparation
CZ2017298A3 (cs) 2017-05-26 2018-12-05 Zentiva, K.S. Amorfní formy obeticholové kyseliny
CN107286160A (zh) * 2017-06-05 2017-10-24 毛佳婧 一种抗肝炎药物的哌啶并吡啶并吡唑‑锌配合物的制备方法
US12478612B2 (en) 2017-06-30 2025-11-25 Cindome Pharma, Inc. Deuterated domperidone compositions, methods, and preparation
CN109280071A (zh) * 2017-07-19 2019-01-29 东莞东阳光药物研发有限公司 奥贝胆酸的晶型及其制备方法
CA3070837A1 (en) 2017-07-24 2019-01-31 Intercept Pharmaceuticals, Inc. Isotopically labeled bile acid derivatives
US11161872B2 (en) 2017-08-03 2021-11-02 Medytox Inc. Methods for preparing bile acids
CN107383139A (zh) * 2017-08-09 2017-11-24 杭州和泽医药科技有限公司 一种3α‑羟基‑7‑氧代‑5β‑胆烷酸新衍生物制备奥贝胆酸的方法
CN109485687A (zh) * 2017-09-12 2019-03-19 成都弘达药业有限公司 奥贝胆酸的晶型j及其制备方法
JP2020536529A (ja) 2017-10-10 2020-12-17 チルドレンズ ホスピタル メディカル センター 食道組織および／または臓器組成物およびそれを作製する方法
US10611793B1 (en) 2017-11-27 2020-04-07 Teva Czech Industries S.R.O. Solid state forms of obeticholic acid salts
WO2019106043A1 (en) 2017-11-29 2019-06-06 Hexal Ag Pharmaceutical composition comprising obeticholic acid
EP3720867A1 (en) 2017-12-08 2020-10-14 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
WO2019126626A1 (en) 2017-12-21 2019-06-27 Children's Hospital Medical Center Digitalized human organoids and methods of using same
US11434256B2 (en) 2018-01-25 2022-09-06 Msn Laboratories Private Limited, R&D Center Process for the preparation of 3α,7α-dihydroxy-6α-ethyl-5β-cholan-24-oic acid
CN108440629A (zh) * 2018-03-16 2018-08-24 丽珠集团新北江制药股份有限公司 一种制备奥贝胆酸中间体及奥贝胆酸的方法
WO2019197962A1 (en) * 2018-04-09 2019-10-17 Biophore India Pharmaceuticals Pvt. Ltd Crystalline forms of (3α, 5β, 6α, 7α)-6-ethyl-3, 7-dihydroxycholan-24-oic acid (obeticholic acid) and processes thereof
CN110655550A (zh) * 2018-06-29 2020-01-07 江苏海悦康医药科技有限公司 (E)-3α-羟基-6-亚乙基-7-氧代-5β-胆甾烷-24-酸的制备方法
CN108794558B (zh) * 2018-07-03 2020-05-22 丽珠集团新北江制药股份有限公司 一种反应条件温和的奥贝胆酸制备方法
EP3826652B1 (en) 2018-07-26 2026-02-25 Children's Hospital Medical Center Hepato-biliary-pancreatic tissues and methods of making same
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
WO2020039449A1 (en) * 2018-08-24 2020-02-27 Solara Active Pharma Sciences Limited An improved process for the preparation of obeticholic acid and intermediates used in the process thereof
EP3849568A4 (en) 2018-09-12 2022-06-15 Children's Hospital Medical Center Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
AU2019374797A1 (en) * 2018-11-08 2021-05-27 Intercept Pharmaceuticals, Inc. Methods of using obeticholic acid
CN109535217B (zh) * 2018-11-13 2020-04-14 丽珠集团新北江制药股份有限公司 一种奥贝胆酸的精制方法
PE20211907A1 (es) 2019-01-15 2021-09-28 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4)
KR102725082B1 (ko) 2019-02-19 2024-11-04 길리애드 사이언시즈, 인코포레이티드 Fxr 효능제의 고체 형태
EA202193334A1 (ru) 2019-05-30 2022-03-14 Интерсепт Фармасьютикалз, Инк. Фармацевтические композиции, содержащие агонист fxr и фибрат, для применения при лечении холестатического заболевания печени
AU2020283048A1 (en) 2019-05-31 2021-12-23 Children's Hospital Medical Center Shaped organoid compositions and methods of making same
CN114206900A (zh) 2019-05-31 2022-03-18 萨奇治疗股份有限公司 神经活性类固醇及其组合物
EP3976066A4 (en) 2019-05-31 2023-06-28 Children's Hospital Medical Center Methods of generating and expanding hematopoietic stem cells
WO2021029656A1 (ko) * 2019-08-14 2021-02-18 주식회사 바이오톡스텍 하이드로퀴논 유도체, 및 오베티콜릭산을 포함하는 비알콜성 지방간염의 예방 또는 치료용 약학조성물
CN112824425B (zh) * 2019-11-21 2023-10-03 成都西岭源药业有限公司 一种6-位烯基取代胆酸化合物及其制备方法和应用
WO2021231539A1 (en) * 2020-05-13 2021-11-18 Children's Hospital Medical Center Alleviation of liver injury by activating the signaling pathway mediated by farnesoid x receptor
WO2022051321A1 (en) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a fxr agonist
KR102526452B1 (ko) * 2020-10-28 2023-04-27 (주)델로 관절 구조를 포함하는 토이 로봇
CN114644670A (zh) * 2020-12-17 2022-06-21 四川弘远药业有限公司 奥贝胆酸和对氨基苯甲酸的共晶及其制备方法
CN114236027B (zh) * 2021-12-22 2024-01-12 中山百灵生物技术股份有限公司 一种(E)-6-亚乙基-3α-羟基-7-酮基-5β-胆甾烷-24-酸的检测方法
US12343351B2 (en) 2022-03-25 2025-07-01 Rutgers, The State University Of New Jersey Pulmonary function treatment

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072695A (en) * 1972-09-21 1978-02-07 Intellectual Property Development Corporation 3α,7α-Dihydroxy-cholanic acid derivatives
IT1137459B (it) * 1981-04-14 1986-09-10 Erregierre Spa Prodesso per la preparazione di acido ursodeossicolico ad alta purezza
EP0101554B1 (en) 1982-07-29 1986-10-15 Lehner A.G. New derivatives of biliary acids, process for the production thereof and pharmaceutical compositions containing the same
IT1206112B (it) 1983-04-29 1989-04-14 Lehner Ag Nuovi derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche.
IT1212835B (it) 1983-08-18 1989-11-30 Lehner Ag Derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche.
US4892868A (en) 1984-08-17 1990-01-09 Gipharmex, S.P.A. Derivatives of biliary acids, process for the production thereof and corresponding pharmaceutical compositions
IT1196377B (it) 1984-12-21 1988-11-16 Lehner Ag Derivati di acidi biliari,procedimento per la loro preparazione e relative composizioni farmaceutiche
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
IT1223313B (it) 1987-10-20 1990-09-19 Gipharmex Spa Derivati di acidi biliari loro preparazione e composizioni farmaceutiche che li contengono
JPH0320265A (ja) * 1989-02-10 1991-01-29 Meiji Seika Kaisha Ltd アミノチアゾール酢酸誘導体並びにその製造法
US5175320A (en) 1989-04-17 1992-12-29 Giuliani S.P.A. Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
IT1229570B (it) 1989-04-17 1991-09-04 Giuliani Spa Derivati fluorurati di acidi biliari, loro preparazione e composizioni farmaceutiche che li contengono.
EP0433899B1 (en) 1989-12-13 1995-04-12 Mitsubishi Chemical Corporation New pyrazolyl acrylic acid derivatives, useful as systemic fungicides for plant and material protection
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
PL331148A1 (en) 1996-07-12 1999-06-21 Smithkline Beecham Plc Novel method of treating the leptin immunity
JP3600713B2 (ja) 1997-08-06 2004-12-15 東京応化工業株式会社 ポジ型ホトレジスト組成物
US6008237A (en) 1997-12-19 1999-12-28 Merck & Co., Inc. Arylthiazolidinedione derivatives
EP1053227B1 (en) 1998-01-29 2008-11-05 Amgen Inc. Ppar-gamma modulators
JP3146187B2 (ja) * 1998-06-26 2001-03-12 高砂香料工業株式会社 ジホスフィンオキシドの新規な製造方法
WO2000025134A1 (en) 1998-10-23 2000-05-04 Glaxo Group Limited Assays for ligands for nuclear receptors
JP2002532729A (ja) 1998-12-23 2002-10-02 グラクソ グループ リミテッド 核内受容体のリガンドのアッセイ
US6465258B1 (en) 1999-01-07 2002-10-15 Tularik, Inc. FXR receptor-mediated modulation cholesterol metabolism
US20020132223A1 (en) 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
EP1473042B1 (en) 1999-03-26 2006-06-21 City of Hope Screening for FXR receptor modulators
DE60013417T2 (de) 1999-03-26 2005-09-15 City Of Hope, Duarte Verfahren zum screenen von fxr-rezeptormodulatoren
US6906057B1 (en) 1999-06-11 2005-06-14 Allergan, Inc. Methods for modulating FXR receptor activity
JP2003501477A (ja) 1999-06-11 2003-01-14 アラーガン・セイルズ・インコーポレイテッド Ｆｘｒ受容体活性を調節する方法
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
CA2386750A1 (en) 1999-10-22 2001-05-03 Merck & Co. Inc. Pharmaceuticals for treating obesity
US6627636B2 (en) 2000-06-15 2003-09-30 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
AU2001288623A1 (en) 2000-09-05 2002-03-22 Tularik, Inc. Fxr modulators
US20020119958A1 (en) 2001-02-13 2002-08-29 Shinichiro Tojo Therapeutic agent for hyperlipidemia
EP1392714B1 (en) 2001-03-12 2005-08-31 Intercept Pharmaceuticals, Inc. Steroids as agonists for fxr
WO2002084286A1 (en) 2001-04-12 2002-10-24 Takeda Chemical Industries, Ltd. Screening method
US20070010562A1 (en) 2001-08-13 2007-01-11 Ulrike Bauer Nr1h4 nuclear receptor binding compounds
ATE381542T1 (de) 2001-08-13 2008-01-15 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
EP1423113A4 (en) 2001-08-13 2007-04-18 Phenex Pharmaceuticals Ag NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
MXPA04004657A (es) * 2001-11-14 2004-08-13 Teva Pharma Formas amorfas y cristalinas de potasio de losartan y proceso para su preparacion.
US20030144360A1 (en) 2001-11-19 2003-07-31 Allergan Sales, Inc. Composition and method for modulating BAR/FXR receptor activity
AU2003225903A1 (en) 2002-03-21 2003-10-08 Curagen Corporation Methods of using farnesoid x receptor (fxr) agonists
CA2482195A1 (en) 2002-04-12 2003-10-23 The University Of Chicago Farnesoid x-activated receptor agonists
US6987121B2 (en) 2002-04-25 2006-01-17 Smithkline Beecham Corporation Compositions and methods for hepatoprotection and treatment of cholestasis
ITMI20021532A1 (it) 2002-07-12 2004-01-12 Roberto Pellicciari Composti chimici
EP1562915A1 (en) 2002-11-22 2005-08-17 SmithKline Beecham Corporation Farnesoid x receptor agonists
EP1696910A4 (en) 2003-09-26 2009-12-09 Smithkline Beecham Corp COMPOSITIONS AND METHOD FOR THE TREATMENT OF FIBROSIS
EP1568706A1 (en) * 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
TW200603818A (en) * 2004-03-11 2006-02-01 Fresenius Kabi De Gmbh Conjugates of hydroxyethyl starch and erythropoietin
US9498484B2 (en) 2004-03-12 2016-11-22 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using FXR ligands
AU2005272916A1 (en) * 2004-08-10 2006-02-23 Exelixis, Inc. Heterocyclic compounds as pharmaceutical agents
US20060252670A1 (en) * 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient
CA2814247C (en) 2005-04-25 2016-01-19 Genaera Corporation Polymorphic and amorphous salt forms of squalamine dilactate
ITMI20050912A1 (it) * 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
JP2007077123A (ja) 2005-09-16 2007-03-29 Shiono Chemical Co Ltd 非晶質セフジニル、その製造方法およびこれを含有する経口投与用医薬組成物
DK2040713T3 (da) 2006-06-27 2014-09-29 Intercept Pharmaceuticals Inc Galdesyrederivater som fxr-ligander til forebyggelsen eller behandlingen af fxr-medierede sygdomme eller tilstande
EP1894924A1 (en) * 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
CL2007003035A1 (es) * 2006-10-24 2008-05-16 Smithkline Beechman Corp Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
EP1947108A1 (en) 2007-01-19 2008-07-23 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
WO2008091540A2 (en) 2007-01-19 2008-07-31 Intercept Pharmaceuticals, Inc. 23-substituted bile acids as tgr5 modulators and methods of use thereof
US8338628B2 (en) * 2007-08-28 2012-12-25 City Of Hope Method of synthesizing alkylated bile acid derivatives
US7825258B2 (en) * 2007-11-15 2010-11-02 Hoffmann-La Roche Inc. Methyl-benzimidazole derivatives
AU2009276507B2 (en) 2008-07-30 2015-11-19 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
WO2010039529A2 (en) * 2008-09-23 2010-04-08 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treament of inflammatory disease
SG10201400162QA (en) 2008-11-19 2014-05-29 Intercept Pharmaceuticals Inc Tgr5 modulators and methods of use thereof
CN102712672B (zh) 2009-08-25 2016-09-14 胆清医药有限公司 用于治疗胆疾病的多羟基化胆汁酸
CN102121547B (zh) * 2010-12-23 2013-01-16 拉卡萨安吉拉股份有限公司 用于管道接头的衬套和采用该衬套的管道接头
CN102372757B (zh) 2011-10-31 2013-01-16 安徽科宝生物工程有限公司 酯化法制备猪胆汁中鹅去氧胆酸的方法
SG10201607230SA (en) 2012-06-19 2016-10-28 Intercept Pharmaceuticals Inc Preparation, Uses And Solid Forms Of Obeticholic Acid

Also Published As

Publication number Publication date
KR20190121871A (ko) 2019-10-28
BR112014031828B1 (pt) 2021-12-21
EP3336097A1 (en) 2018-06-20
TWI673284B (zh) 2019-10-01
EA201990211A1 (ru) 2019-06-28
JP2015521621A (ja) 2015-07-30
AU2016200832A1 (en) 2016-02-25
US10155787B2 (en) 2018-12-18
US20160215014A1 (en) 2016-07-28
NZ703072A (en) 2016-06-24
CA2877122A1 (en) 2013-12-27
ES2822375T3 (es) 2021-04-30
EA201590040A1 (ru) 2015-05-29
AU2016200832B2 (en) 2017-05-18
JP2020125317A (ja) 2020-08-20
EP3336097B1 (en) 2020-08-19
KR20180083966A (ko) 2018-07-23
CO7240414A2 (es) 2015-04-17
AU2013277429A1 (en) 2015-01-22
EP3992201A1 (en) 2022-05-04
CA3028207A1 (en) 2013-12-27
PT3336097T (pt) 2020-10-29
CA3047776C (en) 2022-10-18
JP2017075169A (ja) 2017-04-20
AU2020202405A1 (en) 2020-04-30
PH12014502835A1 (en) 2015-02-02
SG11201408501UA (en) 2015-01-29
US20160074419A1 (en) 2016-03-17
MX2014016062A (es) 2015-07-17
US20190153020A1 (en) 2019-05-23
IL257841A (en) 2018-04-30
EP2861613A1 (en) 2015-04-22
CA3047776A1 (en) 2013-12-27
BR122016011808B1 (pt) 2021-09-21
JP2018172438A (ja) 2018-11-08
EP3789394A1 (en) 2021-03-10
CN104781272A (zh) 2015-07-15
US9238673B2 (en) 2016-01-19
CA2877122C (en) 2020-04-28
AU2018241172A1 (en) 2018-11-01
BR122016011808A2 (pt) 2018-12-11
NZ734451A (en) 2018-12-21
KR20160143894A (ko) 2016-12-14
MX365059B (es) 2019-05-22
AU2017204057A1 (en) 2017-07-06
CL2014003475A1 (es) 2015-08-07
SG10201610434YA (en) 2017-02-27
AU2013277429B2 (en) 2016-01-14
AU2018241172B2 (en) 2020-03-05
IL261372A (en) 2018-10-31
DK3336097T3 (da) 2020-09-28
US10047117B2 (en) 2018-08-14
EA032347B1 (ru) 2019-05-31
JP6527077B2 (ja) 2019-06-05
SI3336097T1 (sl) 2021-07-30
US20210395293A1 (en) 2021-12-23
KR20150022974A (ko) 2015-03-04
IL236231A0 (en) 2015-02-01
SG10201607230SA (en) 2016-10-28
US20130345188A1 (en) 2013-12-26
HK1211296A1 (en) 2016-05-20
JP6877389B2 (ja) 2021-05-26
US10174073B2 (en) 2019-01-08
NZ719360A (en) 2017-08-25
JP2016074724A (ja) 2016-05-12
KR101881245B1 (ko) 2018-07-23
US9732116B2 (en) 2017-08-15
CN111228278A (zh) 2020-06-05
AU2017204057B2 (en) 2018-11-01
BR112014031828A2 (pt) 2021-07-06
IN2014MN02561A (pl) 2015-09-04
US20170226149A1 (en) 2017-08-10
MX2019005819A (es) 2019-10-21
WO2013192097A1 (en) 2013-12-27
US20250011360A1 (en) 2025-01-09
CL2015002145A1 (es) 2015-12-11
US20230340010A1 (en) 2023-10-26
JP6978544B2 (ja) 2021-12-08
JP2018184443A (ja) 2018-11-22
TW201410699A (zh) 2014-03-16
US20160176913A1 (en) 2016-06-23

Similar Documents

Publication Publication Date Title
PL3336097T3 (pl) Wytwarzanie niekrystalicznej postaci kwasu obetycholowego
ZA201501847B (en) Formulations of enzalutamide
SG11201503646TA (en) Esterification of 2,5-furan-dicarboxylic acid
SG11201504134SA (en) External preparation
IL235802A0 (en) A new process for the preparation of 2-cyclopentyl-6-methoxy-isonicotinic acid
ZA201407677B (en) Nicotine formulation
GB201501016D0 (en) Preparation of 18F-fluciclovine
PL399419A1 (pl) Sposób wytwarzania 4-metoksydihydrochalkonu
PL399418A1 (pl) Sposób wytwarzania 4-metoksydihydrochalkonu
IL236450A (en) Process for making 5-fluoro-h1-pyrazoles
EP2892903A4 (en) PROCESS FOR PREPARING TAZOBACTAM
ZA201405824B (en) Process for the preparation of substituted phenylpropanones
PL2908859T3 (pl) Formulacje arypiprazolu
HUP1200675A2 (en) Process for the preparation of pyrimidinyl-piperazines
GB201210088D0 (en) Odontalgic preparation
PL2890669T3 (pl) Sposób wytwarzania eteru dimetylowego
GB201211247D0 (en) Improved formulation
IL234771A0 (en) Nicotine formulation
PL399423A1 (pl) Sposób wytwarzania 2'-hydroksydihydrochalkonu
PL399422A1 (pl) Sposób wytwarzania 2',4,4',6'-tetrahydroksydihydrochalkonu
PL398695A1 (pl) Sposób wytwarzania 2'-hydroksydihydrochalkonu
GB201206178D0 (en) Formulations
AU2012900977A0 (en) Improvements to the manufacture of biochar-coke